Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response

Autor: Hana Šváchová, Pavel Nemec, L. Kovarova, Zdenek Adam, Miroslav Penka, Ludek Pour, Lucie Burešová, Martina Almáši, Roman Hájek, Tomas Buchler, Jiri Vorlicek
Přispěvatelé: Departement of Internal Medicine-Hematooncology, University Hospital Brno, Czech Myeloma Group, University Research Centre, Institute of Biostatistics and Analyses [Brno] (IBA MED / MUNI), Faculty of Medicine [Brno] (MED / MUNI), Masaryk University [Brno] (MUNI)-Masaryk University [Brno] (MUNI), Departement of Oncology, 1st Faculty of Medicine and Thomayer University Hospital, Departement of Clinical Hematology
Rok vydání: 2009
Předmět:
Adult
Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Therapeutic response
Angiogenesis
Basic fibroblast growth factor
Antineoplastic Agents
Thrombospondin 1
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
High-dose chemotherapy
medicine
Humans
Angiostatins
Aged
030304 developmental biology
0303 health sciences
Angiostatin
Hepatocyte Growth Factor
business.industry
Hematology
General Medicine
Middle Aged
3. Good health
Vascular endothelial growth factor
Vascular endothelial growth factor A
Treatment Outcome
medicine.anatomical_structure
Endocrinology
chemistry
030220 oncology & carcinogenesis
Cytokines
Female
Hepatocyte growth factor
Bone marrow
Endostatin
Multiple Myeloma
business
medicine.drug
Zdroj: Annals of Hematology
Annals of Hematology, Springer Verlag, 2009, 89 (4), pp.385-389. ⟨10.1007/s00277-009-0834-3⟩
ISSN: 1432-0584
0939-5555
DOI: 10.1007/s00277-009-0834-3
Popis: International audience; Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). We have measured concentrations of angiogenesis activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and hepatocyte growth factor (HGF), and inhibitors, including endostatin, thrombospondin-1 (TSP-1), and angiostatin in the peripheral and bone marrow blood of MM patients at diagnosis and after high-dose chemotherapy. We have analyzed 96 patients with secretory MM. Serial measurements of angiogenesis factors/inhibitors were analyzed in the plasma by subgroups based on the best treatment response. Concentrations of angiogenic factors were determined in the peripheral blood and bone marrow plasma. There were significant decreases of VEGF and HGF levels and a significant increase in TSP-1 concentrations in the bone marrow plasma of patients who achieved complete or very good partial response in contrast to those who had partial or no response. VEGF and HGF levels decrease but those of TSP-1 increase after successful treatment for MM, indicating a reduction in the rate of angiogenesis.
Databáze: OpenAIRE
Externí odkaz: